Product Information
FABIOR 0.1% FOAM is a brand product labeled by Mayne Pharma, priced at $12.3228 per GM under NDC 51862029510. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on May 11, 2012.
Strength
1 mg/g
Manufacturer
Mayne PharmaNDC
51862029510
Classification
Brand
Dosage Form
AEROSOL, FOAM
Route
TOPICAL
Effective Date
6/17/2026
Active Ingredients
TAZAROTENEApproval Type
New Drug (NDA)
FDA Application
NDA202428FDA Approved
5/11/2012
On Market Since
3/10/2017
Pharmacological Classes
Price Statistics
The NADAC for FABIOR 0.1% FOAM has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3228 per GM |
|---|---|
| All-time high | $12.4913 (Apr 15, 2026) |
| All-time low | $11.7471 (Jun 19, 2024) |
| 52-week high | $12.4913 |
| 52-week low | $12.3228 |
| Median price | $12.3669 |
| Average price | $12.2787 |
| Largest weekly change | +5.0% (Oct 9, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tazarotene market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mayne Pharma manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tazarotene market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FABIOR 0.1% FOAM?
The current National Average Drug Acquisition Cost (NADAC) for FABIOR 0.1% FOAM, manufactured by Mayne Pharma, is $12.3228 per GM (NDC 51862029510), effective Sep 30, 2026.
How has the price of FABIOR 0.1% FOAM changed over time?
Over the history we have for it, the NADAC for FABIOR 0.1% FOAM has risen 4.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for FABIOR 0.1% FOAM?
Since Apr 17, 2024, the NADAC for FABIOR 0.1% FOAM has ranged from a low of $11.7471 (Jun 19, 2024) to a high of $12.4913 (Apr 15, 2026), with a median of $12.3669 per GM.
Are there cheaper alternatives to FABIOR 0.1% FOAM?
No other NADAC-published product currently shares the active ingredient and strength of FABIOR 0.1% FOAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FABIOR 0.1% FOAM?
FABIOR 0.1% FOAM (NDC 51862029510) is labeled by Mayne Pharma, and CMS classifies it as a brand product.